<DOC>
	<DOC>NCT01414114</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of KAI-4169 in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis subjects with chronic kidney disease-mineral and bone disorder (CKD-MBD).</brief_summary>
	<brief_title>Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Subjects provides written informed consent Screening intact PTH (iPTH) ≥350 pg/mL and corrected calcium ≥ 8.5 mg/dL Hemoglobin ≥ 8.5 g/dL Serum transaminases (ALT or SGPT, AST or SGOT) less than 2.5 times the upper limit of normal Adequate hemodialysis three times per week History or symptomatic ventricular dysrhythmias History of angina pectoris or congestive heart failure History of myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months History of or treatment for seizure disorder within the last 12 months Postdialysis systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 90 mmHg Serum magnesium below the lower limit of normal at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Clinical Trial, Phase 2</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic kidney disease-mineral and bone disorder</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>